Plain-English translation of NCT05942300 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether , a new oral medication, can work better when combined with chemotherapy for women whose ovarian cancer has returned. The research team believes this medication might help make chemotherapy more effective by blocking a specific resistance mechanism in cancer cells. The goal is to see if this combination can stop the cancer from progressing and give patients a longer disease-free period.
After women with ovarian cancer progress on certain maintenance therapies (like PARP inhibitors), their cancer often becomes harder to treat with platinum-based chemotherapy. This trial exists because doctors need better options for these patients, and early research suggests that blocking a specific protein pathway might help overcome chemotherapy resistance and improve outcomes.
You likely qualify if…
You likely don't qualify if…
You would take as an oral tablet or liquid at home on a daily basis while receiving chemotherapy infusions at the hospital or treatment center. The study is testing two different dose levels of the medication to find the safest and most effective combination. You would have regular visits for blood work, imaging scans, and check-ups to monitor how well the treatment is working and to watch for side effects.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Lan Coffman
Collaborators
Novartis Pharmaceuticals, National Cancer Institute (NCI)
Enrollment target
~30 participants
Started
January 2024
Primary completion
July 2028
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kelsey Mitch, RN
UPMC Magee Women's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.